摘要:
This invention provides a method of MR investigation of a sample, the method comprising: (i) placing in a uniform magnetic field a composition comprising an OMRI contrast agent and an MR imaging agent containing nuclei (MR imaging nuclei) capable of emitting magnetic resonance signals (e.g. the primary magnetic field B0) and capable of exhibiting a T1 relaxation time of 6 s or more (at 37° C. in D2O in a field of 7T); (ii) exposing the composition to a first radiation of a frequency selected to excite electron spin transitions in the OMRI contrast agent; (iii) optionally but preferably separating the whole, substantially the whole, or a portion of said OMRI contrast agent from said MR imaging agent; (iv) administering said MR imaging agent to said sample, (v) exposing the sample to a second radiation of a frequency selected to excite nuclear spin transitions; (vi) detecting magnetic resonance signals from the sample; and (vii) optionally, generating an image or dynamic flow data from the detected signals.
摘要:
The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.3, R.sup.4, R.sup.6 and R.sup.7 each have the meanings set forth in the specification.The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.
摘要:
The present invention discloses compounds of the formula ##STR1## wherein X is C;Y is C;R.sup.4 to R.sup.7 and R.sup.11 to R.sup.13 are as defined herein; or a pharmaceutically-acceptable addition salt thereof. The compounds are useful as pharmaceuticals, for example, in the treatment of stroke, ischemia, anoxia, migraine and psychosis.
摘要:
A multilayer protein film has a mass of greater than 0.5 μg/cm2 and consists essentially of protein. A drug delivery device comprises the multilayer protein film onto which a pharmaceutically active agent can be loaded. A biomedical implant comprises an implant substrate and the multilayer protein film on at least a portion of the implant substrate surface. A method of making a multilayer protein film having a mass of greater than 0.5 μg/cm2 comprises contacting a substrate with a protein solution at a temperature of from about 30° C. to about 95° C., wherein a multilayer protein film having a mass of greater than 0.5 μg/cm2 is formed on the substrate.
摘要翻译:多层蛋白质膜具有大于0.5μg/ cm 2的质量,并且基本上由蛋白质组成。 药物递送装置包括其上可以加载药物活性剂的多层蛋白质膜。 生物医学植入物包括在植入物衬底表面的至少一部分上的植入物基底和多层蛋白质膜。 制备质量大于0.5μg/ cm 2的多层蛋白质膜的方法包括使底物与蛋白质溶液在约30℃至约95℃的温度下接触,其中多层蛋白质膜具有 在基板上形成大于0.5μg/ cm 2的质量。
摘要:
The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).
摘要:
The invention relates to an improved process for preparation of protected DO3A, such as DO3A-tri-t-butyl ester (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tri-t-butyl ester). The compound is prepared as a salt. The process includes a work-up procedure giving DO3A-tri-t-butyl ester as a salt of excellent purity.
摘要:
The present invention relates to: Compounds of formula (I) consisting of a cyclic polymer core A and groups -L-X attached to said core A-(L-X)n (I) wherein A denotes a cyclic polymer which is comprised of 3 or 4 identical monomers which are connected by amide bonds; L may be present or not and if present is that same or different and denotes a linker moiety, X is the same or different and denotes a chelator; and n denotes an integer of 3 or 4; Compound of formula (II) consisting of a cyclic polymer core A and groups -L-X′ attached to said core A-(L-X′)n (H) wherein A denotes a cyclic polymer which is comprised of 3 or 4 identical monomers which are connected by amide bonds; L may be present or not and if present is that same or different and denotes a linker moiety, X is the same or different and denotes a paramagnetic chelate consisting of a chelator X and a paramagnetic metal ion M; and n denotes an integer of 3 or 4; And compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and magnetic resonance spectroscopy (MRS).
摘要:
The present invention provides a process for the preparation of an MR contrast agent, said process comprising: i) obtaining a solution in a solvent of a hydrogenatable, unsaturated substrate compound and a catalyst for the hydrogenation of said substrate compound; ii) introducing said solution in droplet form into a chamber containing hydrogen gas (H2) enriched in para-hydrogen (p-1H2) and/or ortho-deuterium (o-2H2) whereby to hydrogenate said substrate to form a hydrogenated imaging agent; iii) optionally subjecting said hydrogenated imaging agent to a magnetic field having a field strength below earth's ambient field strength; iv) optionally dissolving said imaging agent in an aqueous medium; v) optionally separating said catalyst from the solution of said imaging agent in said aqueous medium; vi) optionally separating said solvent from the solution of said imaging agent in said aqueous medium; and vii) optionally freezing the solution of said imaging agent in said aqueous medium.
摘要:
The present invention provides a method of contrast enhanced magnetic resonance imaging of a sample, said method comprising: a) administering a hyperpolarised MR contrast agent comprising non-zero nuclear spin nuclei into said sample for fluid dynamic investigations of the vasculature, b) exposing said sample or part of the sample to radiation of a frequency selected to excite nuclear spin transitions in said non-zero nuclear spin nuclei, c) detecting MR signals from said sample using any suitable manipulation method including pulse sequences. The invention also provides novel compounds.
摘要:
The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites.